Daiichi Sankyo Files For Japan Approval Of Sanofi-Aventis Rifadin
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo said it has filed for Japanese approval of Rifadin (rifampicin), a drug to treat nontuberculous mycrobacterial disease